Literature DB >> 18390707

CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Shelly J Robertson1, Ronald J Messer, Aaron B Carmody, Robert S Mittler, Christopher Burlak, Kim J Hasenkrug.   

Abstract

Chronic viral infections cause high levels of morbidity and mortality worldwide, making the development of effective therapies a high priority for improving human health. We have used mice infected with Friend virus as a model to study immunotherapeutic approaches to the cure of chronic retroviral infections. In chronic Friend virus infections CD4(+) T regulatory (Treg) cells suppress CD8(+) T cell effector functions critical for virus clearance. In this study, we demonstrate that immunotherapy with a combination of agonistic anti-CD137 Ab and virus-specific, TCR-transgenic CD8(+) T cells produced greater than 99% reductions of virus levels within 2 wk. In vitro studies indicated that the CD137-specific Ab rendered the CD8(+) T cells resistant to Treg cell-mediated suppression with no direct effect on the suppressive function of the Treg cells. By 2 weeks after transfer, the adoptively transferred CD8(+) T cells were lost, likely due to activation-induced cell death. The highly focused immunological pressure placed on the virus by the single specificity CD8(+) T cells led to the appearance of escape variants, indicating that broader epitope specificity will be required for long-term virus control. However, the results demonstrate a potent strategy to potentiate the function of CD8(+) T cells in the context of immunosuppressive Treg cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390707      PMCID: PMC2768524          DOI: 10.4049/jimmunol.180.8.5267

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion.

Authors:  Warren N D'Souza; Leo Lefrançois
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

2.  The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.

Authors:  Guoxing Zheng; Bin Wang; Aoshuang Chen
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

3.  4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity.

Authors:  David Cooper; Pratima Bansal-Pakala; Michael Croft
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

4.  In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.

Authors:  Linda Diehl; Geertje J D van Mierlo; Annemieke T den Boer; Ellen van der Voort; Marieke Fransen; Liesbeth van Bostelen; Paul Krimpenfort; Cornelis J M Melief; Robert Mittler; Rene E M Toes; Rienk Offringa
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

5.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Molecular and biological characterization of human 4-1BB and its ligand.

Authors:  M R Alderson; C A Smith; T W Tough; T Davis-Smith; R J Armitage; B Falk; E Roux; E Baker; G R Sutherland; W S Din
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

7.  IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.

Authors:  Gayle Pulle; Mariana Vidric; Tania H Watts
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

8.  In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Kim J Hasenkrug
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

9.  4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.

Authors:  Beom K Choi; Jun S Bae; Eun M Choi; Woo J Kang; Shimon Sakaguchi; Dass S Vinay; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2003-12-23       Impact factor: 4.962

10.  Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy.

Authors:  R S Mittler; T S Bailey; K Klussman; M D Trailsmith; M K Hoffmann
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

View more
  25 in total

1.  4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.

Authors:  Vaiva Vezys; Pablo Penaloza-MacMaster; Daniel L Barber; Sang-Jun Ha; Bogumila Konieczny; Gordon J Freeman; Robert S Mittler; Rafi Ahmed
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

2.  Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.

Authors:  Fernando Pastor; Despina Kolonias; James O McNamara; Eli Gilboa
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

3.  T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells.

Authors:  Emily R Mercadante; Ulrike M Lorenz
Journal:  J Immunol       Date:  2017-05-26       Impact factor: 5.422

Review 4.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

5.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 6.  The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses.

Authors:  Alison Crawford; E John Wherry
Journal:  Curr Opin Immunol       Date:  2009-03-04       Impact factor: 7.486

Review 7.  Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Authors:  K S Peggs; S A Quezada; J P Allison
Journal:  Clin Exp Immunol       Date:  2009-02-18       Impact factor: 4.330

8.  Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Authors:  Roch Houot; Matthew J Goldstein; Holbrook E Kohrt; June H Myklebust; Ash A Alizadeh; Jack T Lin; Jonathan M Irish; James A Torchia; Arne Kolstad; Lieping Chen; Ronald Levy
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

Review 9.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

10.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Authors:  Rajesh K Sharma; Kutlu G Elpek; Esma S Yolcu; Rich-Henry Schabowsky; Hong Zhao; Laura Bandura-Morgan; Haval Shirwan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.